We also integrated the gene expression data of three CML cell lines and their imatinib-treated CML cells [31] with the top genes associated with BCR-ABL1 in our prediction to prioritize targets whose inhibition can have synergistic effects with imatinib. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.